However, when adding resminostat (5 μmol/l) on IFN-β prestimulated (1,000 U/ml) hepatoma cells, a profound suppression of IFIT-1 expression was observed in HepG2, Hep3B, and PLC/PRF/5 hepatoma cells, but no alteration in the phosphorylation status of STAT1 (Figure 7; lane 4 in all panels). The gene discussed is STAT1; the disease is hepatocellular carcinoma.